<div id="readability-page-1"><p>Novavax (NASDAQ:NVAX - Get Free Report) is expected to post its  Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.44) per share and revenue of $55.63 million for the quarter. Investors may visit the the company's upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.</p><ul><li>Analysts Think These Stocks Could More Than Double in Value</li></ul><p>Novavax (NASDAQ:NVAX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the consensus estimate of ($0.07) by $0.69. Novavax had a negative return on equity of 142.33% and a net margin of 39.20%.The firm had revenue of $239.24 million during the quarter, compared to analysts' expectations of $149.19 million. During the same quarter last year, the firm earned $0.99 earnings per share. The business's revenue for the quarter was down 42.4% on a year-over-year basis.  On average, analysts expect Novavax to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year. </p><h2>Novavax Price Performance</h2><p>Shares of NASDAQ:NVAX traded up $0.03 during midday trading on Friday, hitting $8.46. The company had a trading volume of 749,350 shares, compared to its average volume of 6,281,517. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of 3.71, a price-to-earnings-growth ratio of 0.12 and a beta of 2.74. Novavax has a twelve month low of $5.01 and a twelve month high of $11.55. The company has a debt-to-equity ratio of 5.93, a current ratio of 2.36 and a quick ratio of 2.34. The business's 50-day simple moving average is $8.37 and its 200-day simple moving average is $7.50. </p><h2>Hedge Funds Weigh In On Novavax</h2><ul><li>Is Biotech’s Bull Run Over? Examining Election Impacts</li></ul><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Thrivent Financial for Lutherans purchased a new stake in  Novavax in the 2nd quarter valued at approximately $1,321,000.  State of Wyoming purchased a new stake in  Novavax in the 2nd quarter valued at approximately $52,000.  Headlands Technologies LLC purchased a new stake in  Novavax in the 2nd quarter valued at approximately $903,000.  Tower Research Capital LLC TRC boosted its holdings in  Novavax by 437.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 37,335 shares of the biopharmaceutical company's stock valued at $235,000 after purchasing an additional 30,386 shares in the last quarter.  Finally, E Fund Management Co. Ltd. boosted its holdings in  Novavax by 9.0% in the 2nd quarter. E Fund Management Co. Ltd. now owns 28,280 shares of the biopharmaceutical company's stock valued at $178,000 after purchasing an additional 2,326 shares in the last quarter. Hedge funds and other institutional investors own  53.04% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><p>Several research analysts have recently commented on the company. Bank of America  restated an &#34;underperform&#34; rating and set a $7.00 price target (down from $9.00) on shares of Novavax in a research report on Wednesday, August 20th. HC Wainwright raised their price target on Novavax from $10.00 to $11.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, October 23rd. Cantor Fitzgerald began coverage on Novavax in a research report on Friday, October 24th. They set an &#34;overweight&#34; rating and a $18.00 price target for the company. Finally, Weiss Ratings  reiterated a &#34;sell (d+)&#34; rating on shares of Novavax in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and four have given a Sell rating to the stock. According to MarketBeat.com, the company  has an average rating of &#34;Hold&#34; and an average target price of $11.33.</p><ul><li>Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?</li></ul><p><b>Check Out Our Latest Research Report on NVAX</b></p><h2>About Novavax</h2> (Get Free Report)<p>Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.</p><h2>See Also</h2><ul><li>Five stocks we like better than Novavax</li><li>Compound Interest and Why It Matters When Investing</li><li>Comfort Systems Is the AI Data Center Stock Beating NVDA, AVGO, &amp; AMD</li><li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li><li>Cameco's $80 Billion U.S. Nuclear Deal Changes Everything </li><li>The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number</li><li>NU Stock: U.S. Bank License May Be the Next Growth Catalyst</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlZBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlZBWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Novavax Right Now?</h2><p>Before you consider Novavax, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.</p><p>While Novavax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

NVAX

<p>Novavax (NASDAQ:NVAX) is set to release its Q3 2025 earnings on November 6, with analysts predicting a loss of $0.44 per share and revenue of $55.63 million. The company previously reported a $0.62 EPS for Q2 2025, exceeding expectations. Novavax's stock is currently trading at $8.46, with a market cap of $1.37 billion. Analysts have mixed ratings, with an average target price of $11.33. Institutional investors hold 53.04% of the stock, indicating significant interest in the company.</p>

Novavax (NVAX) to Release Earnings on Thursday